Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder

Abstract

Objective The aim of this study is to investigate the effects of gemcitabine maintenance on progression-free survival (PFS) in patients with metastatic gallbladder cancer (GBC).

Materials and Methods Sixty patients with unresectable or metastatic GBC having ongoing response to treatment with initial six cycles of gemcitabine and a platinum-based doublet chemotherapy were prospectively randomized on day 21 of the 6th cycle in 1:1 fashion to receive either maintenance gemcitabine 1 g/m² intravenously on day 1 and day 8 of three weekly cycle or observation. Survival analysis was performed using the Kaplan–Meier method and comparisons by the log-rank test. A p-value < 0.05 was considered as statistically significant.

Results Of 60 patients, a total of 56 were available for final analysis. The median PFS was 4.7 months (3.1–6.3) in gemcitabine arm and 2.6 months (2.4–2.8) in observation arm, hazard ratio (HR) 0.196 (95% confidence interval [CI]: 0.1–0.39), p < 0.001. Median overall survival in gemcitabine arm was 12.4 months (9.15–15.6) as opposed to 9.9 months (8.29–11.5) in observation arm, HR 0.76 (95% CI: 0.43–1.35), p = 0.354. The grade 3 or 4 side effects in maintenance arm were transaminitis (17.9%), thrombocytopenia (17.8%), neutropenia (14.2%), and febrile neutropenia (7.1%).

Conclusions Maintenance gemcitabine therapy in unresectable/metastatic GBC patients responding to first-line gemcitabine and platinum treatment contributes to increase PFS with minimal and manageable side effects.

Keywords

gallbladder cancer - gemcitabine - maintenance - progression-free survival

Publication History

Article published online:
12 June 2021

• References

• 1 Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006; 118 (07) 1591-1602
• 2 Medina E, Kaempffer AM. [Cancer mortality in Chile: epidemiological considerations]. Rev Med Chil 2001; 129 (10) 1195-1202
• 3 Lazcano-Ponce EC, Miquel JF, Muñoz N. et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51 (06) 349-364
• 4 Nandakumar A, Gupta PC, Gangadharan P, Visweswara RN, Parkin DM. Geographic pathology revisited: development of an atlas of cancer in India. Int J Cancer 2005; 116 (05) 740-754
• 5 Levy AD, Murakata LA, Rohrmann Jr CA. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics 2001; 21 (02) 295-314, 549–555
• 6 Valle J, Wasan H, Palmer DH. et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
• 7 Sharma A, Dwary AD, Mohanti BK. et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28 (30) 4581-4586
• 8 Kanda S, Goto K, Shiraishi H. et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol 2016; 27 (12) 2242-2250
• 9 Zwitter M, Rajer M, Stanic K. et al. Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Cancer Biol Ther 2016; 17 (08) 833-839
• 10 Cathomas R, Crabb SJ, Mark M. et al. Swiss Group for Clinical Cancer Research SAKK. Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: A multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11). Prostate 2016; 76 (16) 1519-1527
• 11 Mirza MR, Monk BJ, Herrstedt J. et al. ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375 (22) 2154-2164
• 12 Ferrero JM, Hardy-Bessard AC, Capitain O. et al. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Cancer 2016; 122 (20) 3119-3126
• 13 Rossi S, Schinzari G, Basso M. et al. Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. Future Oncol 2016; 12 (10) 1299-1307
• 14 Kulkarni S, Vella ET, Coakley N. et al. The use of systemic treatment in the maintenance of patients with non-small cell lung cancer: a systematic review. J Thorac Oncol 2016; 11 (07) 989-1002
• 15 Gallardo JO, Rubio B, Fodor M. et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12 (10) 1403-1406
• 16 Penz M, Kornek GV, Raderer M. et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12 (02) 183-186
• 17 Doval DC, Sekhon JS, Gupta SK. et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004; 90 (08) 1516-1520
• 18 Dingle BH, Rumble RB, Brouwers MC. Cancer Care Ontario’s Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 2005; 19 (12) 711-716
• 19 Wakabayashi H, Ishimura K, Hashimoto N, Otani T, Kondo A, Maeta H. Analysis of prognostic factors after surgery for stage III and IV gallbladder cancer. Eur J Surg Oncol 2004; 30 (08) 842-846
• 20 Kayahara M, Nagakawa T, Nakagawara H, Kitagawa H, Ohta T. Prognostic factors for gallbladder cancer in Japan. Ann Surg 2008; 248 (05) 807-814